Staphylococcus aureus has colonized humans for at least 10 000 years, and today inhabits roughly a third of the population. In addition, S. aureus is a major pathogen that is responsible for a significant disease burden, ranging in severity from mild skin and soft-tissue infections to life-threatening endocarditis and necrotizing pneumonia, with treatment often hampered by resistance to commonly available antibiotics. Underpinning its versatility as a pathogen is its ability to evade the innate immune system. S. aureus specifically targets innate immunity to establish and sustain infection, utilizing a large repertoire of virulence factors to do so. Using these factors, S. aureus can resist phagosomal killing, impair complement activity, disrupt cytokine signalling and target phagocytes directly using proteolytic enzymes and cytolytic toxins. Although most of these virulence factors are well characterized, their importance during infection is less clear, as many display speciesspecific activity against humans or against animal hosts, including cows, horses and chickens. Several staphylococcal virulence factors display species specificity for components of the human innate immune system, with as few as two amino acid changes reducing binding affinity by as much as 100-fold. This represents a major issue for studying their roles during infection, which cannot be examined without the use of humanized infection models. This review summarizes the major factors S. aureus uses to impair the innate immune system, and provides an in-depth look into the host specificity of S. aureus and how this problem is being approached.
STAPHYLOCOCCUS AUREUS
Staphylococcus aureus is a facultatively anaerobic, catalasepositive, Gram-positive bacterium of the phylum Firmicutes. It is a normal part of the human microbiota, colonizing the nasal passages of roughly 30 % of the world's population [1, 2] . As S. aureus is a commensal organism, carriers do not often experience disease, yet despite this S. aureus is a major pathogen worldwide and causes a significant disease burden.
Although the carriage of S. aureus is generally asymptomatic, it is associated with an increased risk of infection from the carried strain, placing a large percentage of the population at risk [3] . S. aureus generally resides in the nasal passage, and can also reside on the skin, as observed in specific patients, for example >70 % of individuals with active atopic dermatitis have S. aureus present on their skin [4] . Although predominantly a commensal, S. aureus can establish an infection when the skin or mucosal barriers are breached, causing a broad range of infections depending on the site, and ranging in severity from abscesses to necrotizing pneumonia. S. aureus is predominantly an opportunistic, nosocomial pathogen, and systemic infections typically
THE ROLE OF THE INNATE IMMUNE SYSTEM
To combat staphylococcal infection, the human body is protected by both the adaptive and the innate immunity. At the level of the individual, adaptive immunity is highly specific and long-lived, but is slow to develop due to the necessary acquisition of immune memory followed by the expansion of specific cell types. In contrast, the innate immune system responds rapidly and can recognize a broad number of pathogens including those that have not been encountered before, allowing the body to respond and prevent the initiation of infection as the first line of defence against invading microbes. The innate immune system includes the physical barriers to infection, antimicrobial proteins, receptors that recognize molecules associated with pathogens and phagocytic cells that can engulf and destroy microbes. The function of the innate immune system is to provide protection from invading pathogens by preventing their entry and recognizing and destroying them before they can establish an infection, while it also provides the signals required for efficient activation of the adaptive immune response. The central importance of the innate immune system in host defence against S. aureus is highlighted by the number of staphylococcal factors directly targeting it.
The primary reason for the success of S. aureus as a pathogen is its expression of a broad range of virulence factors, many of which target major components of the innate immune system. Using these factors, S. aureus can target antimicrobial proteins, the complement system, chemotaxis of phagocytic cells, phagocytosis and the oxidative defence to evade destruction by the immune system and establish an infection.
EVASION OF THE ANTIMICROBIAL PROTEINS BY S. AUREUS
The first line of defence an invading microbe encounters is the host barrier tissues, such as the skin, respiratory tract or gut. These tissues contain high concentrations of antimicrobial peptides (AMPs) and enzymes that kill or inhibit the growth of invading microbes. Among the largest of the classes of AMPs are the defensins, which are generally short (12-50 amino acids), positively charged peptides that kill bacteria by disrupting the cell membrane [6] . Where these barriers fail, further immune defences become necessary to prevent infection.
S. aureus employs several virulence factors that target antimicrobial proteins (AMPs) encountered at the skin and mucosal barriers. a-defensin is a dominant AMP produced against S. aureus, and is a small cationic peptide with a hydrophobic region that permits insertion into phospholipid bilayers, disrupting cell membranes. a-defensins are produced abundantly by neutrophils, accounting for 50 % of neutrophil granule proteins, and are secreted into the surroundings or fuse with maturing phagosomes to mediate bacterial killing [7] . Staphylokinase (SAK) is an exoprotein produced by S. aureus that activates plasminogen, in addition to directly binding and inactivating a-defensin [8] . SAK activity represents a major aspect of staphylococcal resistance to defensins, and was also shown to confer resistance to killing by defensins in vivo [8] .
The cathelicidins are a related group of AMPs that possess a conserved N-terminal cathelin domain and a variable C-terminal AMP domain, and exert potent anti-staphylococcal activity. Like a-defensin, they localize with neutrophil granules, and are also inducibly expressed and produced by keratinocytes [9, 10] . The cathelicidin LL-37 is targeted by two staphylococcal enzymes known as aureolysin and V8 protease, which cleave LL-37 and render it inactive [11] . V8 protease targets a single residue, while aureolysin cleaves at three distinct sites, suggesting that aureolysin is more specialized towards disrupting LL-37 [11] . Disruption of LL-37 is clearly an important step in the establishment of skin infections by S. aureus, as demonstrated by the downregulation of LL-37 levels during atopic dermatitis that predisposes people to S. aureus infections [4, 12] . However, this also indicates that S. aureus is unable to fully disrupt LL-37 activity, suggesting a degree of natural resistance to LL-37 targeting during normal infection.
Lysozyme is a muramidase found in mucous secretions, including tears, saliva, sweat and serum [13] . Lysozyme kills bacteria by attacking cell wall peptidoglycan, cleaving between the glycosidic b-1, 4-linked residues of N-acetylmuramic acid and N-acetylglucosamine. S. aureus resists lysozyme using the O-acetyltransferase enzyme OatA, which O-acetylates muramic acid residues present in cell wall peptidoglycan [14] ; this modification blocks lysozyme activity by creating a steric hindrance between the cell wall and the active site of the enzyme. In addition to OatA, DltA [15] and MprF [16] also modify the cell wall by changing negatively charged residues (of cell wall teichoic acid and phosphatidylglycerol, respectively) into positively charged residues. This allows S. aureus to repel cationic AMPs, including a-defensin and cathelicidins, enhancing virulence by conferring resistance to neutrophil killing [16] and dampening innate immune signalling by TLR2 [17, 18] . These enzymes highlight how S. aureus modifies the cell surface to evade recognition and destruction by the innate immune system.
STAPHYLOCOCCAL EVASION OF THE COMPLEMENT SYSTEM
After overcoming the AMPs found at the epithelial barriers, S. aureus must then contend with the complement system. The complement system is a cascade of over 30 proteins that 'complement' the immune response (reviewed in [19] ). Complement carries out three main functions during infection: opsonization of the bacterial surface to enhance phagocytosis, generation of inflammatory signals to recruit phagocytes and the destruction of pathogens by the formation of the membrane attack complex (MAC). There are three distinct pathways of complement: the classical, lectin and alternative pathways. Each is initiated in a different way, with early proteins acting as proenzymes that sequentially cleave the next protein. Importantly, all three converge with the cleavage of C3 by a C3 convertase. Cleavage of C3 produces C3a, a potent chemoattractant, and C3b, which opsonizes pathogens by binding covalently with the pathogen surface, promoting phagocytosis and other effector functions. C3b that is bound to the pathogen surface is able to form a proteolytic complex with other complement components, amplifying the cascade by cleaving more C3 and depositing more C3b at the cell surface. Acting in a complementary manner to other aspects of immunity, the complement system is essential to normal immune function. For this reason, evasion of complement is a priority for many pathogenic bacteria [20] [21] [22] . S. aureus utilizes a wide arsenal of virulence factors that disrupt complement, effectively impairing opsonization, inflammatory signalling, chemokine production, phagocyte recruitment and bacterial killing (summarized in Fig. 1 ).
The classical complement pathway relies on opsonization of the bacterial surface by immunoglobulins to function, and they are consequently targeted by several virulence factors to subvert complement. Protein A (SpA) is one of the best characterized virulence factors of S. aureus, and associates with the cell wall in addition to being secreted into the surrounding environment. This 42 kDa protein contains five highly homologous regions that are capable of binding antibody fragments, at both the Fcg-effector portion and the Fab antigen recognition region. In addition to directly preventing antibody-mediated effector functions, binding of the Fcg region by SpA blocks activation of the classical complement pathway by preventing C1q binding to antibody-antigen complexes at the cell surface [23] . Furthermore, SpA is also implicated in the progression of staphylococcal pneumonia by directly binding the TNF-a receptor TNFR1, which is present at high levels in the airway epithelia [24] .
After the discovery of SpA, a second virulence factor with strong anti-opsonic properties was discovered, and aptly named as the second immunoglobulin-binding protein (Sbi) [25, 26] . Sbi is secreted into the surrounding milieu and Fig. 1 . Evasion of the complement system by staphylococcal virulence factors. Virulence factors used by S. aureus to evade the complement system. Virulence factors are shown in orange. Protein A (SpA), second immunoglobulin-binding protein (Sbi) and staphylococcal superantigen-like 7 (SSL7) exhibit broad complement inhibition by binding C3 and C5, and specific inhibition of the classical pathway by binding antibodies. S. aureus recruits host plasminogen to the bacterial surface, which is converted into the serine protease plasmin by staphylokinase; the bacterial surface-associated plasmin can then be used to degrade IgA and C3b. The C3 molecule is broadly manipulated by S. aureus: extracellular fibrinogen-binding protein (Efb) binds to the C3d region of C3, preventing cleavage and C3b deposition; aureolysin cleaves C3, resulting in its inactivation by factor H; extracellular complement-binding protein (Ecb) binds C3b to prevent convertase formation, and inactivates it by forming a tripartite complex with factor H. The staphylococcal complement inhibitor (SCIN) targets active C3 convertases, and effectively stops complement by binding and stabilizing them. The chemotaxis inhibitory protein of staphylococcus (CHIPS) prevents C5aR signalling by binding the N-terminus of the receptor. The S-subunits of g-haemolysin CB (HlgC) and Panton-Valentine leukocidin (LukS-PV) also interfere with C5aR signalling by competing with C5a.
anchored to the cell envelope by binding lipoteichoic acid [27, 28] . It possesses two N-terminal domains that bind the Fcg fragment of IgG [25, 26] , and two other domains that can bind C3 [29] . Consequently, Sbi provides broad protection against opsonophagocytosis and complement, as is illustrated by sbi mutant strains being more susceptible to killing by human neutrophils and complement-mediated lysis in vitro [27] . As part of a class of toxins that are related to the staphylococcal superantigens, staphylococcal superantigen-like 7 (SSL7) is also able to target immunoglobulins. SSL7 binds to IgA1 and IgA2, disrupting IgA interactions with cell-surface FcaRI, and preventing FcaRI-mediated phagocytosis [30] . SSL7 also binds C5 from a range of species [30] , blocking the production of the C5a chemoattractant and formation of the membrane attack complex (MAC).
Staphylokinase (SAK) can disrupt the complement system in addition to targeting a-defensins. SAK exploits the host factor plasminogen, an inactive zymogen that is found in the blood and is activated by cleavage into the active serine protease, plasmin. In S. aureus, plasminogen is acquired using cell-surface receptors [31] and is then cleaved by SAK into plasmin, producing a bacterial membrane-associated serine protease. S. aureus is then able to utilize plasmin to degrade IgG and C3b, conferring broad anti-opsonic activity and effectively disrupting all complement pathways [32] . Similarly, aureolysin (which targets the AMP LL-37) also disrupts complement by cleaving C3 into C3a and C3b, which are then degraded and inactivated by host factors H and I [33] .
S. aureus is at greatest risk of encountering the complement system while in the blood. Here, S. aureus manipulates its environment by modulating the activities of clotting factors, including fibrinogen and platelets. S. aureus expresses several virulence factors that bind fibrinogen, but the extracellular fibrinogen-binding protein (Efb) also interferes with complement. Efb binds to a region of C3 known as C3d, blocking all complement pathways by preventing C3 cleavage, C3b deposition and C3 convertase formation [34] . Additionally, Efb binding of C3d disrupts the adaptive immune response by preventing the recognition of C3d fragments by B-cells, targeting both arms of the immune system with a single molecule [35] .
A critical aspect of the alternative complement pathway is the distinction of self from non-self, in order to prevent the attack of host cells by complement. A key regulator of this mechanism is complement factor H (FH), which prevents the alternative pathway from proceeding on host cells. It does this by accelerating the decay of the alternative C3 convertase (C3bBb), cleaving surface-associated and fluid-phase C3b into an inactive iC3b form by acting as a cofactor for factor I, and preventing formation of the C3 convertase by competing with factor B in binding to C3b [36] . S. aureus exploits this mechanism by producing the extracellular complement binding protein (Ecb), which can bind C3b [37] . Additionally, Ecb forms a tripartite complex with FH and C3b at the cell surface, utilizing the regulatory activity of FH to inactivate and remove C3b, thereby disrupting complement [37] . Ecb also interferes with the recognition of C3b by neutrophils via complement receptor 1 (CR1), impairing phagocytosis [38] .
During bacterial infection, two of the earliest chemoattractants produced are C5a and the N-formylated tripeptide N-formylmethionyl-leucyl-phenylalanine, or 'fMLF'. To prevent recognition of these molecules by innate immunity, S. aureus secretes the chemotaxis inhibitory protein of staphylococcus (CHIPS), which is produced by 62 % of S. aureus strains and inhibits the cognate receptors of C5a and fMLF -the C5a receptor (C5aR1) and formyl peptide receptor (FPR1) [39] . The 14.1 kDa secreted protein acts by binding the N-terminal ligand-binding regions of C5aR1 and FPR1 using distinct regions of the protein, targeting both receptors simultaneously [40, 41] . The most potent staphylococcal virulence factor that targets the complement system is the staphylococcal complement inhibitor (SCIN). Expressed by 90 % of S. aureus strains, SCIN inhibits complement by directly binding and stabilizing the classical and alternative C3 convertases (C4b2a and C3bBb), preventing the activation of all complement pathways [42] . Although SCIN is regarded as a secreted protein, in the presence of human serum SCIN associates with the bacterial cell surface, indicating direct binding to C3 convertases and preventing further C3b deposition [42, 43] . S. aureus comprehensively targets the complement system to evade immune recognition by attacking central components such as C3b and the C3 convertases, in addition to the anaphylatoxins and their receptors.
EVASION OF HOST PHAGOCYTES BY S. AUREUS
Once a pathogen has accessed the deeper tissues, it is essential that host cells are able to recognize invading cells and respond accordingly to prevent infection. Specialized immune cells known as phagocytes destroy invading microbes by engulfing them directly via phagocytosis, before using a number of antimicrobial proteins and reactive oxygen species (ROS) to kill the pathogen. Recognition of pathogens is made possible by pattern-recognition receptors (PRRs), which recognize specific pathogen-associated molecular patterns (PAMPs). The major PRRs found at the cell surface are the Toll-like receptors (TLRs), which recognize a wide range of PAMPs from different pathogens, including bacterial and fungal PAMPs (e.g. zymosan, lipopolysaccharide and peptidoglycan) and viral PAMPs (single-and double-stranded DNA and RNA) [44] . Once activated, PRRs act against invading pathogens by triggering the production of signalling molecules, recruiting phagocytic cells, generating bactericidal compounds and activating the inflammatory response [45] .
After recognition by the innate immune system, macrophages and neutrophils are the dominant phagocytes recruited to sites of infection, and are required for effective clearance of S. aureus [46] . As S. aureus robustly targets host AMPs and the complement system, phagocytic cells are among its greatest obstacles in establishing an infection. Phagocytes become activated after recognizing PAMPs or inflammatory signals, stimulating amplification of the inflammatory response, activation of the respiratory burst and adherence of phagocytes to endothelial cells to facilitate recruitment to the infection site. Accordingly, S. aureus targets and disrupts each of these processes individually in addition to directly targeting phagocytic cells, drastically impairing their ability to combat the infection (summarized in Fig. 2 ).
During infection, some of the most potent chemoattractants produced by innate immunity are CXCL1, CXCL2, CXCL7 and CXCL8 (also known as IL-8) [47] . CXCR2 is a major chemotactic receptor that is expressed on the surface of neutrophils and recognizes all four of these cytokines. Subsequently, S. aureus secretes the cysteine protease staphopain A (ScpA), which destroys CXCR2 as a functioning receptor [48] . ScpA cleaves the N-terminus of CXCR2, rendering the receptor unable to function, as demonstrated by the absence of receptor signalling in response to CXCL1 or CXCL7, which are CXCR2-specific [48] . However, ScpA is unable to abolish IL-8 signalling, as CXCR1 remains capable of binding CXCL8.
Alongside CXCR2, phagocytes express several other chemotactic receptors, including the C5a receptors (C5aR1 and C5L2) and formyl peptide receptors (FPR1, FPR2 and FPR3). The formyl peptide receptor-like-1 (FPRL1) is closely related to FPR1, and binds a wide range of ligands, Virulence factors are shown in orange. Chemotaxis is broadly targeted by many factors by binding to or disrupting major chemotactic receptors, including complement receptors (C3aR, C5aR and C5L2), CXCR receptors (CXCR1 and CXCR2), CCR receptors (CCR1, CCR2 and CCR5) and FPR receptors (FPRL1, FPR1 and FPR2). Extracellular adhesion proteins (Eap, EapH1 and EapH2) block neutrophil serine proteases (neutrophil elastase, cathepsin G and proteinase 3) that attack bacteria directly or in association with neutrophil extracellular traps (NETs) by noncovalently occluding the catalytic cleft. Staphylococcal enterotoxin-like toxin X (SELX) and staphylococcal superantigen-like 5 (SSL5) disrupt transmigration by binding to glycosylated P-selectin glycoprotein ligand-1 (PSGL-1), impairing the phagocyte's ability to bind selectins and carry out rolling adhesion to reach the site of infection. Pore-forming toxins, including the leukocidins, a-toxin (Hla) and phenol-soluble modulins (PSMs), kill phagocytes outright by forming b-barrel pores in the cell membrane, leading to the leakage of cations and cell lysis. Staphylococcal superantigen-like 3 (SSL3) and PSMs block and modulate Toll-like receptor 2 (TLR2) signalling, disrupting adhesion, generation of reactive oxygen species, IL-8 production and chemokine receptor expression.
including regions of the HIV-1 envelope protein gp41, the AMP LL-37 and fragments of prion peptides [49] [50] [51] . The FPRL1 inhibitory protein (FLIPr) inhibits FPRL1 with high affinity, and is also able to inhibit FPR1 and FPR2, albeit to a much lesser degree [52] . S. aureus also produces a similar protein with 73 % homology with FLIPr, known as FLIPr-like. FLIPr-like is also able to inhibit FPRL1, FPR1 and FPR2, but has a 100-fold greater affinity for FPR1 over FPRL1 [53] . Incubation of neutrophils with FLIPr and FLIPr-like causes a complete loss of chemotactic activity from FPR agonists fMLF and MMK-1, but not C5a, as the C5aR1 remained functional [53] . Additionally, FLIPr and FLIPr-like disrupt antibody-mediated opsonophagocytosis by inhibiting class I, II and III IgG receptors (FcgR) [54] . Beyond mimicry of FPR ligands, a recent study has demonstrated that the FPR2 receptor is targeted in a human-specific manner by staphylococcal superantigenlike 13 (SSL13), highlighting the breadth of targeting with which S. aureus targets the formyl-peptide receptors during infection [55] .
The PRR TLR2 is an important receptor enabling the recognition of S. aureus by host phagocytes by binding peptidoglycan-associated lipoproteins. TLR2 also recognizes di-and triacylated lipoproteins through homotypic interactions with TLR1 and TLR6, respectively [56] . TLR2 plays a key role in anti-staphylococcal immunity in vivo, as TLR20 À/À mice become more susceptible to staphylococcal sepsis and nasal colonization when compared with wild-type mice [57] [58] [59] . S. aureus targets TLR2 using staphylococcal superantigen-like 3 (SSL3), a superantigen that directly binds TLR2, preventing TLR2-mediated neutrophil functions [60] . Consequently, SSL3 disrupts numerous neutrophil functions, including adhesion, ROS generation, production of IL-8 and expression of chemokine receptors, all of which are mediated by TLR2 [60, 61] . In addition to SSL3, S. aureus also indirectly targets TLR2 by shedding bacterial lipoproteins, which is mediated by the surfactant toxins known as phenol-soluble modulins (PSMs) [59] . Most interestingly, the interaction between staphylococcal lipoproteins and TLR2 signalling varies across staphylococcal species, with non-commensal, non-pathogenic Staphylococcus carnosus inducing a fulminant immune response, while the response against S. aureus is comparatively mild, suggesting that immunomodulation and control of TLR2 signalling underpins a major aspect of staphylococcal infection [62] .
To migrate to sites of infection, phagocytes must be recruited from the bloodstream into the tissues. This process is called transmigration, and relies on a series of cell surface carbohydrate-binding proteins known as selectins, which mediate a number of transient cell-cell adhesion interactions. Once selectins are expressed on the cell surface, phagocytes begin to adhere by rolling adhesion before passing into the tissues in a process known as extravasation. There are three groups of selectins: L-selectin, which is expressed by leukocytes; E-selectin, which is present on endothelial cells; and P-selectin, which is found on platelets and can also be induced in endothelial cells in response to inflammatory signals [13] . During transmigration, phagocytes express P-selectin glycoprotein ligand-1 (PSGL-1), allowing them to bind all groups of selectins and begin rolling adhesion [47] . By secreting the staphylococcal enterotoxin-like toxin X (SELX), S. aureus disrupts transmigration by binding to glycosylated PSGL-1, preventing selectin recognition and rolling adhesion [63] . Another virulence factor known as staphylococcal superantigen-like 5 (SSL5) targets PSGL-1 in an identical manner, binding directly to PSGL-1 and interfering with phagocyte recruitment [64] . Additionally, SSL5 is able to bind to the N-terminus of several important chemotactic receptors, preventing C3a-, C5a-, CXCL1-and IL-8-mediated phagocyte activation [65] .
After phagocytosis, phagocytes produce several compounds to aid pathogen destruction. The neutrophil serine proteases (NSPs), including neutrophil elastase, cathepsin G and proteinase 3, play important roles in clearing infection and controlling inflammation. NSPs are stored within the azurophilic neutrophil granules [66] and act extracellularly via neutrophil extracellular traps (NETs), which trap and kill bacteria [67] , or are released into the extracellular milieu to destroy pathogens directly [68] , degrade bacterial virulence factors [69] , or mediate inflammation by cleaving cytokines [70] . Additionally, by acting extracellularly, the NSPs often cause significant damage to host tissues, and are implicated in numerous chronic inflammatory conditions, including cystic fibrosis and chronic obstructive pulmonary disease [70] . During infection, S. aureus counters these three NSPs specifically by producing three extracellular adherence proteins (Eap and functional homologues EapH1 and EapH2), which noncovalently occlude the catalytic cleft and block enzyme activity [71] . Eap exhibits inhibitory activity in the nanomolar range, is expressed during infection in both mice and humans [72, 73] and promotes staphylococcal infection in vivo [71] .
Several virulence factors that target AMPs and the complement system also display direct activity against phagocytic cells. SAK, CHIPS and SCIN inactivate C3 convertases, block immunoglobulin binding and inhibit chemotactic receptor signalling, broadly interfering with phagocyte recruitment and activation. Interestingly, these virulence factors are clustered together in a single pathogenicity island, and are distributed by bacteriophages [74] . Additionally, this cluster contains staphylococcal enterotoxin A (SEA), which disrupts innate immune responses by inhibiting the chemotactic receptors CCR1 and CCR2 [75] .
S. aureus also produces a number of bi-component poreforming toxins with lytic activity against cells, including phagocytes and erythrocytes. To target phagocytes, these toxins recognize cell-surface chemokine receptors such as CXCR2 and C5aR1; one component binds to the receptor, followed by recruitment of the second component, which leads to the formation of a pore in the cell membrane, causing cell lysis (summarized in Fig. 3 ). These toxins cause cell lysis at high concentrations, but at sublytic concentrations they also inhibit receptor signalling by competing with the receptor ligand. Receptor inhibition by pore-forming toxins has been demonstrated with Panton-Valentine leukocidin (PVL), g-haemolysin AB and CB (HlgAB and HlgCB) and leukocidin ED (LukED), together inhibiting C5aR1, C5L2, CXCR1, CXCR2 and CCR5 signalling [76] [77] [78] [79] . Due to the range of inhibitory activity displayed by these toxins, their role in impairing phagocyte function at sublytic concentrations cannot be ignored.
THE STAPHYLOCOCCAL TOXINS
For over 100 years, we have known that S. aureus secretes factors capable of haemolytic and leukocidal activity [80, 81] . S. aureus produces several toxins, including atoxin, phenol-soluble modulins (PSMs) and the bi-component pore-forming leukocidins, all of which emphasize the ability of S. aureus to directly attack host cells and evade destruction.
a-toxin (Hla), along with SpA, is one of the oldest known virulence factors of S. aureus, and is present in the core genome of almost all sequenced strains [82] . Hla was discovered in the late 1920s following the Bundaberg tragedy, where a diphtheria toxin-antitoxin vaccine became contaminated with staphylococci [81] . Thereafter, it was determined that culture supernatants from the contaminating strains could cause haemolysis and lethal injury when injected into rabbits [81] hinting at a prominent role in staphylococcal virulence. Hla is the 'prototypical' b-barrel pore-forming toxin, capable of forming heptameric pores on the surface of a broad range of cell types, including Bcells, T-cells, monocytes and neutrophils [83, 84] . Initially, Hla was thought to target membrane lipids in a similar manner to other identified bacterial toxins [85] , but this failed to explain Hla's unusual cell type and species specificity, and in particular its potent ability to lyse rabbit erythrocytes [86] . Resolving this issue, the protein receptor for Hla was identified as A disintegrin and metalloprotease 10 (ADAM10) [87] , a transmembrane protein that is present on the surface of a variety of cells, where it acts as a sheddase, cleaving ectodomains from other cellular proteins, including E-cadherin [88] and some CXC chemokines [89] . Hla is a dominant virulence factor in numerous infection models, including pneumonia [82] , dermonecrotic skin infection [90] , sepsis [91] , peritonitis [92] , and endocardial Fig. 3 . The mechanism of action of the bicomponent pore-forming leukocidins. The bi-component leukocidins are composed of two distinct subunits, known as the S and F-subunits. Either subunit can initiate pore formation by recognizing and binding the receptor target (usually a G-protein-coupled receptor), followed by recruitment of the other subunit. These subunits then dimerize and insert into the cell membrane, eventually forming a heptamer by alternating insertion of more S and F subunits. Once fully formed, the heptamer undergoes a conformational change and extends, perforating the cell membrane and causing leakage of cations, disrupting cell homeostasis and leading to cell lysis. Evidence suggests that cell death is caused by a highly inflammatory form of programmed cell death known as pyroptosis, which is accompanied by the release of IL-1b after cleavage of pro-IL-1b by caspase-1 (Cas1) (reviewed in [188] ).
and mammary gland infections [93, 94] . Individuals colonized or infected with S. aureus develop serum antibody titres consistent with Hla expression [95, 96] , and those with high titres become resistant to staphylococcal sepsis [97] . Moreover, strains expressing higher levels of Hla exhibit enhanced virulence [82, 98] , highlighting the influential role of Hla in disease severity. Complete summation of the work concerning Hla is beyond the scope of this review, and has been it has been described comprehensively by others [99] .
Phenol-soluble modulins (PSMs) are an important group of toxins associated with highly invasive CA-MRSA infections, and display potent cytolytic activity against erythrocytes and leukocytes [100, 101] . S. aureus encodes seven PSMs split into three subgroups according to protein size, ranging from 20 to 45 amino acids. All seven PSMs are expressed by virtually all strains of S. aureus, and are encoded across three genetic regions in the core genome; this includes PSMa1-4, PSMb1-2 and d-toxin (also known as PSMg) [100] . Most likely, they originally evolved as surfactant molecules due to their importance in channel formation within biofilms [102] , while their cytolytic capacity against host cells appears to have evolved later [103] . Unlike other staphylococcal toxins, PSMs are receptor-independent [104] and therefore target a greater range of cell types [105] . Like other pore-forming toxins [106] , PSMs are highly amphipathic, allowing them to form a-helical pores in lipid membranes to cause cell lysis. PSMa1-4 are particularly cytolytic [100, 101] , and interestingly, this appears to be dependent on their positive charge; for example, d-toxin is neutral and moderately cytolytic, while PSMb1-2 are negatively charged and are non-cytolytic [107] . In CA-MRSA strains, PSMs act as a specific defence mechanism against phagocytic cells to facilitate phagosomal escape [108, 109] , as the expression of PSMs and other virulence factors are predicted to be upregulated after phagocytosis [110] .
Beyond their cytolytic capacity, at sub-micromolar concentrations PSMs are also highly inflammatory peptides that induce migration and activation in both macrophages and neutrophils, and stimulate the release of pro-inflammatory cytokines [100, 104, 111] . PSMs are directly recognized by host cells through FPR2, which has a lower affinity for formylated peptides than FPR1, but is able to recognize numerous peptides involved in chronic inflammation [104, 112] . Interestingly, FPR1 also recognizes PSMs depending on the length of the peptide, as longer PSMs are weaker agonists of FPR1 [113] . As mentioned, FPR2 is also targeted by FLIPr and FLIPr-like, emphasizing the importance of this receptor during staphylococcal infection [52, 53] . Additionally, PSMs mobilize lipoproteins from the staphylococcal cytoplasmic membrane, modulating TLR2 signalling and representing a dominant driver of sepsis among Gram-positive pathogens [59, 114] .
The staphylococcal leukocidins are a particularly broad and important group of toxins in S. aureus. They are 'bi-component' toxins, secreted as two soluble monomers that combine to form a b-barrel pore in the cell membrane and induce cell lysis (summarized in Fig. 3 ). Of this group, five are associated with human infections: PVL, HlgAB, HlgCB, LukED and leukocidin AB (LukAB). These toxins target a range of leukocyte receptors to lyse host cells.
All bi-component leukocidins are composed of two distinct subunits, including an S-subunit (S for slow migration through chromatography columns) and an F-subunit (fast migration) [115] . After secretion, these subunits oligomerize into a heptamer to induce pore formation, with the exception of LukAB, which is produced as a single heterodimeric molecule [116] . Until recently, these toxins were believed to induce pore formation by initial binding of the S-subunit to the molecular target, which then permitted recruitment of the F-subunit [117] . This model has been challenged by the observation that the F-subunit of LukF-PV is able to target leukocyte common antigen (CD45), which is expressed on the surface of all nucleated immune cells [118] . This is significant, as it contradicts the current model of toxin activity, and provides a rationale to explain functional redundancy between some toxins, for example, PVL and HlgCB are both known to target the C5a receptor [77, 78] .
Almost all bi-component leukocidins target chemokine receptors that are highly expressed on the surface of phagocytes. Most of these receptors are from the class A rhodopsin-like family of G-protein-coupled receptors (GPCRs) (with the exception of CD11b, DARC and CD45). This family of structurally and functionally related seven-transmembrane loop receptors is important for transducing extracellular signals through interactions with cytosolic G-proteins [119] . LukAB is an exception, as it does not target a GPCR, and instead targets CD11b [also known as Mac-1 integrin or complement receptor 3 (CR3)], an important C3b-binding receptor that is expressed on the surface of monocytes, macrophages and neutrophils, and governs phagocytosis, bacterial killing and chemotaxis [116, 120, 121] . Uniquely, the S-subunits of HlgAB and LukED (HlgA and LukE) can also target the Duffy antigen/receptor for chemokines (DARC) on erythrocytes, an atypical chemokine receptor that is not coupled to a G-protein [122] . S. aureus targets the DARC using HlgAB and LukED to liberate essential iron from haemoglobin after lysing erythrocytes, as free iron is scarce during infection due to restriction by the host as a form of 'nutritional immunity' [123] .
Leukocidins are a vital part of S. aureus infection. They are expressed during infection in vivo, and are likely to be a prominent aspect of pathogenesis, as infected individuals produce antibodies against them [124, 125] . Mutant strains lacking PVL, HlgAB, HlgCB or LukAB exhibit a reduced cytolytic activity in vitro [77, 78, 126] , and LukED mutant strains become attenuated in vivo [79] . Despite their evident significance during infection, the overall purpose of leukocidin production has been difficult to determine due to a disconnect between animal models and the species specificity of many of these toxins. Notably, in vitro studies using murine leukocytes demonstrate a resistance to PVLmediated cytolytic activity [78, 127] , and in vivo models of skin and soft-tissue infections, sepsis and pneumonia report no effect of PVL beyond minor and strain-dependent observations [82, 128, 129] . These negative findings are due to the differential expression of other virulence factors, such as Hla, in these strains, and the absence of the human targets C5aR1 and CD45, which are specifically targeted by LukS-PV and LukF-PV, respectively [82, 118] . Moreover, HlgCB and LukAB are also human-adapted, representing another major obstacle for investigation of the roles and functions of these toxins during infection in vivo [77, 116, 126] .
EVADING THE HOST OXIDATIVE DEFENCE
After reaching the site of infection, phagocytes engulf and destroy invading pathogens when they are unsuccessful in avoiding the innate immunity. After phagocytosis, pathogens are initially contained in a vacuole called the phagosome that rapidly fills with microbicidal compounds. This is achieved by fusion of the phagosome with lysosomes or cytotoxic granules, which contain enzymes that degrade bacterial cell walls, proteins and DNA, and produce a respiratory burst that generates antimicrobial ROS, including superoxide (O 2 -), hydrogen peroxide (H 2 O 2 ), hypochlorous acid (HOCl), hydroxyl radicals (.OH) and nitric oxide (NO). In an attempt to survive the phagosome, S. aureus produces several proteins and enzymes that mitigate the level of bactericidal compounds, and directly inhibit central enzymes and compounds in the respiratory burst (summarized in Fig. 4 ).
During the respiratory burst, the first toxic compound produced is superoxide (O 2 -). O 2 -is generated by phagosomal NADPH oxidase, which transfers electrons from NADPH in the cytoplasm onto molecular oxygen in the phagosome, creating the O 2 -free radical. Despite having a high reduction potential, O 2 -is considered to be a relatively ineffective oxidant that causes little damage or cell death, partly as it is easily dismutated by bacterial enzymes such as superoxide dismutase [130] . To resist O 2 -in the phagosome, S. aureus produces two superoxide dismutases, SodA and SodM, which convert O 2 -into H 2 O 2 , using manganese as a cofactor. These enzymes are upregulated after phagocytosis and are evidently important in resisting oxidative killing in the phagosome, as illustrated by an increased susceptibility to oxidative killing in sodA mutant strains [131, 132] . Additionally, recent studies found that high levels of dietary manganese are associated with increased susceptibility to staphylococcal endocarditis, as a result of the enhanced potential of S. aureus to detoxify O 2 -using SodA and SodM [133] . Furthermore, SodM is expressed at significantly higher levels in S. aureus strains isolated from late-stage cystic fibrosis (CF) patients, suggesting that SodM is important for adapting to long-term persistence environments [134] .
To counter O 2 -produced by the host, most strains of S. aureus isolated from humans produce staphyloxanthin, a carotenoid pigment that gives S. aureus its characteristic yellow-orange colour [135] . Staphyloxanthin is a potent antioxidant, and possesses numerous conjugated double bonds that allow it to quench O 2 - [136] . Non-pigmented crt mutant strains grow normally, but are susceptible to nitrosative stress and hypochlorous acid (HOCl), and are more easily cleared by the innate immune system [137, 138] . Additionally, non-pigmented strains show reduced survival and virulence in murine models of subcutaneous and systemic infection, emphasizing the importance of staphyloxanthin in evading oxidative killing [138, 139] .
After the production of O 2 -, hydrogen peroxide (H 2 O 2 ) is generated by both host and bacterial superoxide dismutases. H 2 O 2 is unlikely to be the primary oxidant responsible for bacterial killing in the phagosome, as a milllimolar range of H 2 O 2 is thought to be required for bactericidal activity in vitro, and H 2 O 2 levels in the phagosome generally do not rise above the micromolar range [140] . This notion is controversial, however, as contrasting studies have shown that H 2 O 2 -mediated bactericidal activity occurs in the micromolar range in vitro after controlling for the catalytic effect of iron in resisting oxidative damage [141] , suggesting that phagocytes rely on H 2 O 2 to enhance bacterial killing [142] . S. aureus resists H 2 O 2 using its catalase KatA, which converts two H 2 O 2 molecules to two H 2 O molecules and O 2 using a haem cofactor. Catalase is an important determinant of pathogenicity, as KatA is upregulated after phagocytosis and catalase production is correlated with virulence [143, 144] . Despite this, catalase-negative strains retain virulence [145] , and katA mutant strains are not attenuated in a murine abscess model [146] ; however, they do exhibit impaired nasal colonization, suggesting that catalase is also important for resisting H 2 O 2 produced by bacterial competitors such as S. pneumoniae [147] .
S. aureus also expresses an alkyl hydroperoxide reductase composed of two subunits, AhpF and AhpC. These are reactive towards alkyl peroxides (peroxides that form with organic molecules) and H 2 O 2 . Alkyl peroxides are broken down into the corresponding alcohol and water, or water and molecular oxygen in the case of H 2 O 2 . Little is known about this enzyme, although it appears to be important for pathogenesis through enhancing resistance to oxidative stress, as demonstrated by the reduced colonization of an ahpC mutant in a murine model of nasal colonization [148] .
Hypochlorous acid (HOCl) is generally considered to be the most potent oxidative product produced in the phagosome [149] . HOCl is produced as the result of enzymatic conversion by myeloperoxidase (MPO), generating HOCl from H 2 O 2 and a chloride ion. HOCl is the active compound in bleach, and exhibits a high level of bactericidal activity towards many species of bacteria [150] [151] [152] . Rather than targeting HOCl, S. aureus produces a virulence factor that directly inhibits MPO, blocking production of HOCl. The staphylococcal peroxidase inhibitor (SPIN) is expressed by >90 % of S. aureus strains, and inhibits MPO by occluding the active site, effectively blocking production of HOCl [153] . The SPIN gene (spn) is upregulated within 20 min post-phagocytosis, and SPIN mutants (spn) exhibit an increased susceptibility to oxidative killing, suggesting that SPIN is an important component of surviving the oxidative defence, and that MPO is a key enzyme potentiating the antibacterial activity of neutrophils [153] .
Phagocytes also produce reactive nitrogen species such as nitric oxide (NO) and peroxynitrite (ONOO -) to destroy pathogens, but S. aureus is relatively resistant to nitrosative stress. In mice, the impact of NO in killing S. aureus during infection is limited, while its importance during Salmonella enterica serovar Typhimurium infection is critical [154, 155] . S. aureus possesses one virulence factor that alleviates nitrosative stress, the haemoglobin-like protein flavohaemoglobin (Hmp), and can exert numerous enzymatic activities, including NO-reductase, NO-dioxygenase and alkyl hydroperoxide reductase [156] , making Hmp a versatile enzyme for tackling reactive oxygen and nitrogen species. In Escherichia coli, Hmp converts ÁNO to nitrate during aerobic conditions, and to N 2 O during anaerobic conditions, as well as exhibiting NADH-dependent alkyl hydroperoxide reductase activity [157] [158] [159] . Although little is known about Hmp's role during staphylococcal infection, it is upregulated during microaerobic/anaerobic conditions and during nitrosative stress, and is required for survival at high concentrations of NO [160, 161] .
HOST ADAPTATION OF S. AUREUS
S. aureus is a highly versatile pathogen that colonizes a wide array of different hosts as a result of extensive host-switching events occurring over the last 5000-6000 years [162] . While S. aureus is a commensal organism in humans, it has also been isolated from a wide variety of different vertebrate species, highlighting its capacity to survive in diverse host environments [163] . S. aureus causes disease in a wide variety of economically important animal species, including cows, sheep, goats, poultry and rabbits, and represents a major economic problem in several countries [164] . Intramammary infections in dairy cows cause mastitis, constituting a considerable economic burden [165] , and mastitis in smaller ruminants is also an issue in countries that rely on sheep and goat cheese [166] . In poultry, S. aureus is capable of skeletal infections such as osteomyelitis, and in continental Europe it causes skin abscesses, mastitis and septicaemia in rabbit farms [167, 168] . Importantly, strains derived from animal infections are genotypically and phenotypically different from human strains [169] , but, according to evolutionary evidence, many animal-associated strains of S. aureus originated in humans [162, 170, 171] , highlighting their versatility in colonizing different hosts, and the importance of humans in driving their evolution.
Host adaptation of S. aureus is highly complex, involving changes to the core genome and the acquisition of mobile genetic elements (MGEs) that encode distinct antibiotic resistance plasmids and virulence factors, enabling evasion of the host innate immunity and adaptation to the unique environment presented by a new host. An overview of the numerous host-specific virulence factors produced by S. aureus is shown in Fig. 5 . Changes to the cell surface that may reduce immune recognition are clearly an important feature of host adaptation, as bovine and galline strains possess pseudogenes of prominent surface proteins, such as protein A (SpA) and clumping factor A (ClfA), suggesting that they are unnecessary for colonization in these hosts [172, 173] and that pseudogenes are also an important aspect of host adaptation [162] . In other hosts, immunoglobulin-binding proteins, including SpA and the second immunoglobulin binding protein (Sbi), are highly conserved, and display broad activity across many mammalian IgGs [174] . However, they are unable to form insoluble complexes in ungulates (cows, sheep, goats and horses) [174] , suggesting a diminished effectiveness of Ig-binding in these hosts and supporting the observation of a minimized reliance on surface proteins in bovine strains.
Another common feature of animal-derived strains is the secretion of a host-specific von Willebrand factor-binding protein (vWfbp) that binds the serum glycoprotein von Willebrand factor (vWf), which is involved in the clotting cascade; unique vWfbps are observed in bovine, ovine and equine strains of S. aureus [175, 176] . Bovine strains often carry a unique leukocidin pair known as LukMF, which binds to a CCR1 chemokine receptor expressed only on bovine neutrophils [177] . Interestingly, leukocidins may be a major aspect of host adaptation, as another novel leukocidin named LukPQ has been identified in equine strains, which targets equine CXCRA and CXCR2 [178] .
Expression of host proteins can also influence susceptibility to virulence factors. a-toxin (Hla) exerts potent cytolytic activity against rabbit erythrocytes [86, 179] and murine alveolar epithelial cells [82] as a result of the comparatively high expression of ADAM10 on the cell surface [99] . Contrastingly, Hla is unable to lyse human erythrocytes at low concentrations, exhibiting unique host receptor-dependent specificity [82, 99] . Other notable host-adapted virulence factors include two distinct SCINs, one bovine-and one equine-specific, and a galline cysteine protease similar to staphopain A, demonstrating that complement, Fig. 5 . Host-specific virulence factors and their roles in evasion of the innate immunity. Shown are the numerous virulence factors used by S. aureus to subvert the innate immunity and establish infection. The presence of species-specific targeting is denoted by colour: equine-specific (pink), bovine-specific (green), galline-specific (orange), human-specific (red) and no species specificity (blue). antimicrobial proteins and phagocytes are also important targets for infection in animal hosts [175, 180, 181] .
HUMAN ADAPTATION OF S. AUREUS
S. aureus has colonized humans for at least 10 000 years, according to evolutionary evidence of a human-to-cattle host jump shortly after their domestication [182] . Because of this longstanding relationship, S. aureus has become highly specialized to the environment of the human body. The result is the existence of a wide range of virulence factors that are only functional against the human variant of their target, almost all of which are directed against central components of the innate immune system (Table 1. ).
As shown in Table 1 and Figure 5 , S. aureus produces many human-specific virulence factors that target major components of the innate immune system. There is minimal variation in the presence of virulence factors that are associated with human infection, which is surprising given the high level of variation in the core and accessory genomes of individual strains [183] . Mobile genetic elements (MGEs) are a major determinant of human specificity, and are disseminated by bacterial viruses named bacteriophages, which insert their viral DNA into the genome of the host. An important class of bacteriophages governing human adaptation of S. aureus are the b-haemolysin-converting bacteriophages (bC-'S), which disrupt expression of the b-haemolysin toxin when integrating their DNA into the S. aureus genome [184] .
The most significant MGE that allows S. aureus to colonize and infect humans is the immune evasion complex (IEC), which is disseminated by a bC-'S. The IEC is expressed by roughly 90 % of human isolates, and is almost entirely absent from livestock-derived strains [74, 171] Other human-specific factors expressed by the majority of S. aureus strains are staphopain A (ScpA), the staphylococcal peroxidase inhibitor (SPIN), g-haemolysin CB (HlgCB) and leukocidin AB (LukAB), all of which are found in the core genome of over 99 % of S. aureus strains [153, 187, 188] . ScpA is unable to cleave murine CXCR2, although a single amino acid substitution was able to confer cleavage at high concentrations [48] . SPIN is transcribed near the a genomic island nSaa, close to a cluster of immune evasion factors that includes the staphylococcal superantigen-like toxins [153] . SPIN is unable to inhibit murine, bovine, equine and rabbit myeloperoxidase, and is only active against human MPO [153] . The two bi-component leukocidins, HlgCB and LukAB, are also transcribed in the core genome and expressed by roughly 99.5 % of human isolates; both exhibit an inability to kill murine leukocytes, and are highly cytotoxic to human and primate leukocytes [77, 116] . Panton-Valentine leukocidin (PVL) Kills leukocytes, inhibits chemotaxis at sublytic concentrations C5aR1, C5L2 [78] gÀhaemolysin CB (HlgCB) Kills leukocytes, inhibits chemotaxis at sublytic concentrations C5aR1, C5L2 [77] Leukocidin AB (LukAB) Kills leukocytes CD11b [116] Staphylococcal peroxidase inhibitor (SPIN)
Mitigates ROS production by blocking the active site of MPO Myeloperoxidase (MPO) [153] Staphopain A (ScpA) Inhibits chemotaxis and phagocyte activation by cleaving the IL-8 receptor CXCR2 [48] Staphylococcal superantigen-like 13 Inhibits chemotaxis and phagocyte activation by blocking FPR2 FPR2 [55] FPRL1 inhibitory protein (FLIPr) Inhibits chemotaxis and phagocyte activation by blocking FPR receptors FPRL1, FPR1, FPR2 [52] Iron-regulated surface determinant system (IsdB)
Binds haemoglobin Haemoglobin [190] Additionally, there are numerous surface-associated factors expressed in the core genome that are human-specific; SdrG, a bacterial adhesin from Staphylococcus epidermidis and IsdB, which binds haemoglobin, are unable to bind murine fibrinogen and haemoglobin, respectively, while a mouse model that expresses the human variants of these targets can be used for in vivo studies [189, 190] .
Although these factors are expressed in almost all S. aureus strains, PVL is a notable exception. PVL is disseminated on the latent bacteriophage 'Sa2, and is expressed in only 1.2 % of S. aureus strains [191] . Although PVL is only found in a small minority of strains, it is important to note that it is expressed in almost all CA-MRSA isolates and acts as an epidemiological marker of these infections [192] . Immortalized monocyte-like U937 cells transfected with either the human, primate, mouse or rabbit C5a receptor and treated with PVL demonstrate that PVL is unable to lyse primate or mouse neutrophils in vitro, and is specifically active against the human C5a receptor [78] . Unexpectedly, PVL was also able to lyse cells transfected with the rabbit C5a receptor, which may be explained by a greater amino acid similarity between the rabbit and human receptors compared with other mammals. Rabbit leukocytes are susceptible to PVL lysis in vivo, and a single amino acid mutation in a humanadapted strain is sufficient to confer infectivity in rabbits, suggesting that rabbits are a more representative model of S. aureus infection than mice [128, 193] .
Studying the activity of human-specific virulence factors during infection remains an important obstacle for staphylococcal research. While the mouse has proven extremely useful in determining the roles of virulence factors and host pathways during infection, it has been unable to predict successful vaccine candidates in humans, suggesting a disconnect between the mouse model and human infection [194] . To overcome this problem, humanized mouse models have been created that more closely represent human infection. Humanized mice can be generated by acquiring non-obese diabetic/severe combined immunodeficient mouse with a null mutation in the IL2R common gamma chain (NSG) mice that lack T-cells, B-cells, NK cells, complement and healthy myeloid cells, and engrafting them with human CD34 + stem cells, allowing the human immune system to be reconstituted in a mouse model [195] . These mice are significantly more susceptible to staphylococcal disease, require lower doses to cause infection, and experience higher bacterial burdens compared with non-humanized mice [196] [197] [198] . Additionally, knock-in mice expressing human proteins can be generated using a Cre-lox recombination-mediated approach, as performed with human C5a receptor 1 knock-in (hC5aR1 KI ) mice in which the murine C5aR gene has been replaced with the human gene [199] . hC5aR1 KI mice intraperitoneally infected with S. aureus experience 100-1000-fold higher bacterial burdens within the spleen and kidneys compared with wild-type mice, and become susceptible to targeting and cell lysis by the poreforming leukocidin HlgCB [118] . Interestingly, recent developments of zebrafish models of staphylococcal infection [200, 201] have provided important insights into staphylococcal pathogenesis [202] and have demonstrated complementarity with mouse models [203] , potentially representing a useful alternative to existing systems.
Although these findings are valuable steps towards gaining a more complete understanding of staphylococcal virulence, generating humanized mice requires a significant investment in time and money, and consequently other models to investigate the contribution of human-specific virulence factors to staphylococcal infection in vivo are required, and would greatly benefit the search for an effective vaccination strategy.
CONCLUSIONS
Subverting the innate immune system is an integral part of staphylococcal infection. Utilizing an impressive array of virulence factors, S. aureus counters every aspect of the host defence by disrupting the complement system, impeding the chemotaxis and function of phagocytic cells, and resisting oxidative stress encountered in the phagosome. While many of these factors are well understood, it is apparent that several possess functional specificity to precise residues, which often restricts them to infecting a given host. Consequently, a considerable number of factors are only active within the context of a human infection, and therefore their contribution to infection cannot be modelled outside of a humanized host. This obstacle is limiting our understanding of staphylococcal infection and impeding the search for an effective candidate for vaccination against this pathogen. It is critical that future studies address this gap in our understanding, which can be closed by utilizing new approaches involving humanized infection models. Until then, we cannot fully understand S. aureus infection in humans.
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